GlassScriptPhysician profile
Nagy H Morsi
NPI 1205827128
$3,150.66
in general payments reported to CMS, 2019-2025
19 companies · $737 in 2025
The $737 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $353 · 2020: $262 · 2021: $350 · 2022: $483 · 2023: $367 · 2024: $598 · 2025: $737.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,703.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,702.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $756.10 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $517.17 | 2019-2024 | Trulance, Xifaxan |
| Janssen Biotech, INC. | $497.37 | 2019-2025 | Tremfya, Stelara, Simponi |
| Intercept Pharmaceuticals, INC. | $263.79 | 2020-2025 | Ocaliva |
| Ironwood Pharmaceuticals, INC | $239.12 | 2020-2024 | Linzess |
| Ucb, INC. | $148.24 | 2019-2020 | |
| Ardelyx, INC. | $138.91 | 2024-2025 | Ibsrela |
| Pfizer INC. | $122.36 | 2019-2025 | |
| Celgene Corporation | $70.86 | 2022-2024 | Zeposia |
| Ferring Pharmaceuticals INC. | $58.73 | 2020-2021 | |
| Allergan, INC. | $55.98 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $54.53 | 2019-2022 | |
| Nestle Healthcare Nutrition INC. | $52.02 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $44.12 | 2019 | |
| Phathom Pharmaceuticals, INC. | $39.95 | 2024-2025 | Voquezna |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $32.26 | 2024-2025 | Resmetirom, Rezdiffra |
| Regeneron Healthcare Solutions, INC. | $29.30 | 2025 | Dupixent |
| Ambu INC. | $15.51 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $14.34 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nagy Morsi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.